Circulating MicroRNAs (miRNAs) Respond to Denosumab Treatment After 2 Years in Postmenopausal Women With Osteoporosis—the MiDeTe study
Authors' conclusion
Two years of DMAB treatment resulted in upregulation of 7 miRNAs, 4 of which are mainly transcribed in monocytes, indicating a potential impact of DMAB on circulating osteoclast precursor cells. These changes were associated to BMD gain and BTM suppression and could therefore be useful for monitoring DMAB treatment response.
Study context
- Population
- Postmenopausal women with osteoporosis on denosumab (DMAB) therapy
- Participants
- 21 women
- Outcome
- Circulating miRNAs during DMAB treatment
- Follow-up
- 2 years
Methodological detailssingle-centre, longitudinal
- Single-centre
- Longitudinal
Main finding
As reported in the abstract
miRNAs confirmed by reverse transcription quantitative polymerase chain reaction (RT-qPCR) as significantly changed over 2 years vs baseline
7
Of these, mainly transcribed in blood cells, incl. monocytes
4
Observational data: associations, not effects.
Further findings
Bone mineral density (BMD) and bone turnover markers (BTM) change during treatment
- Hip BMD increase
- 5.5%, P = 0.0006
- Lumbar spine BMD increase
- 11.4%, P = 0.017
- CTX decrease
- 64.1%, P < 0.0001
- P1NP decrease
- 69.3%, P < 0.0001
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →